Therapeutics News and Research

RSS

Dual-targeted therapy shows promise against metastatic triple-negative breast cancer

A new preclinical study suggests that attacking triple-negative breast cancer (TNBC) in two ways at once can kill cancer cells, slow tumor growth and limit the cancer's spread. Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) developed the approach.

23 Oct 2026

Psilocybin reshapes brain connections through distinct cellular pathways

A new study led by researchers at the University of California, Santa Cruz, reveals how psilocybin, the psychoactive compound in "magic mushrooms," reshapes neural connections in the brain.

22 Oct 2026

Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

Modus Therapeutics Holding AB (publ) announces that the manuscript based on the Phase Ib study SEVUSMART in severe malaria, lead-authored by Professor Kathryn Maitland of Imperial College London with co-authors from the SMAART consortium including members such as University College London and the University of Oxford, has been published today in the peer-reviewed journal Nature Communications, following independent peer review.

22 Oct 2026

Needle-free mRNA vaccines protect mice against COVID-19 and flu

A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way to deliver mRNA vaccines while limiting unwanted inflammation.

22 Oct 2026

ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC).

21 Oct 2026

Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the imaging CRO to support Celea’s Phase 3 SURPASS-IPF clinical trial.

From Qureight 21 Oct 2026

ScionxBio announces collaboration to develop long-acting xRNA therapeutics

ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio's proprietary TERA® platform.

From ScionxBio 21 Oct 2026

UC Davis Health introduces five-day accelerated treatment for severe depression

UC Davis Health has added an accelerated treatment approach for depression at its Advanced Psychiatric Therapeutics (APT) clinic in East Sacramento.

20 Oct 2026

Experts weigh risks of using gene therapies for common diseases

Gene therapy is no longer the future of medicine - it's reality. Treatments that replace, silence or edit genes are already changing clinical care.

20 Oct 2026

Scientists find a way to boost the body's natural viral defenses

Washington State University researchers have discovered how to "crank up" a natural defense system in the body to combat viral infection, potentially opening a new door for treating virus infections, cancer, neurological disorders and other diseases.

20 Oct 2026

Study explores potential breast cancer benefits of neurokinin receptor antagonists

Neurokinin receptor (NKR) antagonists are already widely used for treating menopausal hot flashes, representing a highly effective nonhormone treatment.

20 Oct 2026

Researchers use mitochondrial uncouplers to target breast cancer metastasis

Mitochondrial serine catabolic pathway (MSCP), also called serine, glycine, and one-carbon metabolism, is essential for cancer cells to produce amino acids, one-carbon units, and reducing equivalents.

19 Oct 2026

First patient dosed in Phase 1 clinical trial of new cancer drug

On August 18, 2026, in Japan, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio SHIMIZU, administered DS1025 to the first patient worldwide as part of a global, multicenter First-in-Human Phase 1 clinical trial sponsored by Daiichi Sankyo.

19 Oct 2026

New imaging technique detects subtle skin changes in scleroderma patients

Scleroderma (systemic sclerosis) is a rare, chronic, autoimmune disease that causes the body to produce too much collagen, leading to the hardening and thickening of the skin and internal organs.

14 Oct 2026

Precise brain circuit targeting may improve depression treatment outcomes

Stimulation of specific brain connections was associated with sustained improvement in people receiving deep brain stimulation (DBS) for treatment-resistant depression, Mount Sinai researchers reported.

14 Oct 2026

New project receives $2.3 million to develop a database and AI model to identify therapeutic peptides

A group of scientists led by Joseph Brown, assistant professor at the Leslie Dan Faculty of Pharmacy, has received $2.3 million USD in funding to develop a database and AI training model to identify peptides with therapeutic potential.

14 Oct 2026

Novel gene rejuvenation therapy preserves cell identity while reversing age

Every organ and tissue progressively loses function and integrity as it ages. In fact, researchers have identified "hallmarks of aging" that not only present specific processes impacted by age, but are also thought of as levers that, if successfully targeted, could help turn back the aging clock and result in tissue rejuvenation.

14 Oct 2026

New immune profiling tool identifies antibodies that trigger preterm births

A typical pregnancy lasts 40 weeks, but for about 1 in 10 pregnant women labor begins too soon. Premature or preterm birth is the leading cause of newborn deaths worldwide.

14 Oct 2026

Undecimal Bio launches with $18 million oversubscribed seed financing to address ‘liver trap’ in siRNA therapeutic delivery

Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribed $18 million USD seed financing.

From UndecimalBio 13 Oct 2026

Study identifies Piezo channels as targets for orthodontic care

A new review in Genes & Diseases highlights Piezo channels as important biological links between mechanical forces and the cellular processes that shape the face, move teeth and influence oral health.

12 Oct 2026